This article is more than 5 years old. Information may no longer be current.
Santen launches Verkazia in Europe to treat VKC in children
Click Here to Manage Email Alerts
Santen U.K. Ltd. announced the launch of Verkazia eye drops in Europe for the treatment of severe vernal keratoconjunctivitis in adolescents and children at least 4 years old.
Verkazia (0.1% cyclosporine), an immunomodulator that targets the underlying cause of the inflammation at the surface of the eye, controls the allergic response and inflammation.
It has been shown to relieve the most common symptoms of VKC over a 12-month period, according to a press release from Santen.
The recommended dose will be one drop administered four times a day in each affected eye. The drops will be provided in boxes of 120-unit dose vials.
"We strongly welcome the launch of Verkazia, as it is one of the first eye drops to have a license for use in children with severe allergic eye disease known as vernal keratoconjunctivitis. This license is based on clear evidence of its beneficial effect in children with this condition, which is becoming more common in the U.K.,” Abdul-Jabbar Ghauri, MD, consultant ophthalmologist, Sandwell and West Birmingham Hospitals NHS Trust, said in the release.